Cardiol Therapeutics (CRDL) financial statements

Healthcare · Drug Manufacturers - Specialty & Generic · Market cap $138M

Net income was -34M CAD.

Free cash flow was -24M CAD.

The diluted share count rose 191% over the period (dilution).

Revenue and free cash flow

Fiscal years, $ billions (CAD).

-0.0-0.0-0.000.0202020212022202320242025RevenueFree cash flow
Embed this chart

Free to use in articles and newsletters with the source line. Paste this HTML:

Income statement

Fiscal years, in CAD, from Cardiol Therapeutics's 10-K filings with the SEC.

Fiscal year202020212022202320242025
Revenue—78,760 CAD————
Research and development11M CAD11M CAD19M CAD14M CAD14M CAD14M CAD
Selling, general and admin10M CAD28M CAD22M CAD16M CAD26M CAD20M CAD
Operating income-21M CAD-39M CAD-41M CAD-30M CAD-40M CAD-34M CAD
Income tax0 CAD0 CAD0 CAD———
Net income-21M CAD-32M CAD-31M CAD-28M CAD-37M CAD-34M CAD
EPS (diluted)-0.69 CAD-0.73 CAD-0.49 CAD-0.44 CAD-0.51 CAD-0.39 CAD
Diluted shares30M43M63M64M72M87M
Operating margin—-49091.9%————
Net margin—-40170.4%————

Balance sheet

Fiscal years, in CAD, from Cardiol Therapeutics's 10-K filings with the SEC.

Fiscal year202020212022202320242025
Cash and short-term investments14M CAD84M CAD59M CAD35M CAD31M CAD21M CAD
Receivables5,793 CAD65,739 CAD209,923 CAD142,745 CAD100,366 CAD55,727 CAD
Inventory17,968 CAD—————
Total current assets15M CAD87M CAD61M CAD36M CAD32M CAD24M CAD
Property, plant and equipment479,554 CAD356,493 CAD295,738 CAD337,058 CAD195,592 CAD118,093 CAD
Total assets16M CAD88M CAD62M CAD37M CAD32M CAD24M CAD
Total current liabilities3M CAD12M CAD10M CAD8M CAD7M CAD6M CAD
Total liabilities3M CAD12M CAD10M CAD8M CAD7M CAD6M CAD
Shareholders' equity13M CAD76M CAD52M CAD28M CAD25M CAD18M CAD
Net debt-14M CAD-84M CAD-59M CAD-35M CAD-31M CAD-21M CAD

Cash flow

Fiscal years, in CAD, from Cardiol Therapeutics's 10-K filings with the SEC.

Fiscal year202020212022202320242025
Operating cash flow-9M CAD-24M CAD-27M CAD-25M CAD-25M CAD-24M CAD
Capital spending40,602 CAD12,916 CAD74,709 CAD64,312 CAD21,290 CAD24,484 CAD
Free cash flow-9M CAD-24M CAD-27M CAD-25M CAD-25M CAD-24M CAD
Stock-based compensation3M CAD8M CAD5M CAD4M CAD14M CAD11M CAD
Free cash flow margin—-29904.2%————
Every line, every quarterThe deep dive has fifteen-plus years of statements, quarterly results, charts and valuation models for CRDL.
Open CRDL in Investingly

Questions

How much free cash flow does Cardiol Therapeutics generate?

-24M CAD in fiscal 2025 (operating cash flow minus capital spending).

From Cardiol Therapeutics's annual reports filed with the SEC (XBRL data), standardised by Investingly. Information only, not investment advice.